• Validation of the development of CER-001 in ophthalmology
• Key step to launch a clinical study in a new severe indication
Toulouse, FRANCE, Lakeland, UNITED STATES, March 14, 2024, 6:00 p.m. – ABIONYX Pharma, (FR0012616852 – ABNX – PEA PME eligible), new generation biotech company dedicated to the discovery and development of innovative therapies based on apoA alone- I natural recombinant in the world, announces aid for innovation of nearly 1 million euros by Bpifrance. The purpose of this aid is to support the drug candidate CER-001 dedicated to the treatment of a severe indication in ophthalmology.
To receive information from ABIONYX Pharma in real time, send a request to [email protected].